DAFTAR PUSTAKA

Alhasan SA, Aranha O, Sarkar FH. 2001. Genistein elicits pleiotropic molecular
effects on head and neck cancer cells. Clin Cancer Res; 7(12):4178-
4181.

Andrew PJ, Mayer B. 1999. Enzymatic function of nitric oxide synthases.

Cardiovasc Res; 43:521531.

Al-Hijji J, Andolf E, Laurini R, Batra S. 2003. Nitric oxide synthase activity in

human trophoblast, term placenta and pregnant myometrium. Reprod
Biol Endocrinol; 1:51.

Ale-Agha, N, Dyballa-Rukes N, Jakob S, Altschmied J, Haendeler J. 2014.

Cellular functions of the dual-targeted catalytic subunit of telomerase,
telomerase reverse transcriptase Potential role in senescence and
aging. Exp Gerontol; 56:189-193.

Argyle DJ, Nasir L. 2003. Telomerase: a potential diagnostic and therapeutic tool
in canine oncology. Veterinary Pathol; 40:17.

Argyle DJ, McKevitt T, Gault E, Nasir L. 2004. Evaluation of telomerase targeted

therapies in canine cancer cell lines. Vet & Comp Oncol; 2: 214221.

Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-

based environment for protein structure homology modelling.
Bioinformatics 2006; 22:195-201.

Bamberger AM, Jenatschke S, Schulte HM, Loning T, Bamberger MC. 2000.

Leukemia Inhibitory Factor (LIF) stimulates the human HLA-G promoter
in JEG3 choriocarcinoma cells. J Clin Endocrinol Metab; 85(10):3932-
3936.

Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson JA, Nilsson S. 1998.

Differential response of estrogen receptor a and estrogen receptor b to
partial estrogen agonists/antagonists. MolvPharmacol; 54:105112.

Base SN, Kim SJ. Telomerase activity in complete hydatidiform mole. Am J

Obstetric Gynecol 1999; 180(2Pt 1):328-333.

Ben-Porath I, Weinberg RA. 2004. When cells get stressed: an integrative view of
cellular senescence. J Clin Invest; 113:813.

Blackburn ER, Bhattacharyya A, Gilley D. 1997. The telomere and telomerase:

how do they interact? Ciba Found Symp; 211:213.

Blackburn EH, Greider CW, Szostak JW. 2006. Telomeres and telomerase: the
path from maize, Tetrahymena and yeast to human cancer and aging.
Nature Medicine; 12:11331138.

82
Blasco MA. 2005. Telomeres and human disease: ageing, cancer and beyond.
Nature Rev Genetics; 6:611622.

Bliedtnera A, Zieraua O, Albrechtb S, Liebhabera S, Vollmera G. 2010. Effects of

genistein and estrogen receptor subtype-specific agonists in ArKO mice
following different administration routes. Molecular & Cell Endocrinology;
314:4152.

Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB,
Shay JW, Lichtsteiner S, Wright WE. 1998. Extension of life-span by
introduction of telomerase into normal human cells. Science; 279:349
352.

Bondar G, Kuo J, Hamid N, Micevych P. 2009. Estradiol-induced estrogen

receptor- trafficking. J Neurosci; 29:1532315330.

Burger AM, Dai F, Schultes M, Reszka AP, Moore MJ, Double JA, Neidle S.
2005. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor
growth, consistent with telomere targeting and interference with
telomerase function. Cancer Res; 65:14891496.

Catania MA, Crupi A, Firenzuoli F, Parisi A, Sturiale A, Squadrito F, Caputi AP,

Calapai G. 2002. Oral administration of a soy extract improves
endothelial dysfunction in ovariectomized rats. Planta Med 68:1142
1144.

Campisi J. 2003. Cancer and ageing: rival demons?. Nat Rev Cancer; 3:339
349.

Campisi J. 1997. Aging and cancer: the double-edged sword of replicative

senescence. J Am Geriatrics Soc; 45:482488.

Campisi, J., 2001. Cellular senescence as a tumor-suppressor mechanism.

Trends in Cell Biol; 11:S27S31.

Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS,
Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko
V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M. 2006. Genome-
wide analysis of estrogen receptor binding sites. Nat Genet; 38:1289
1297.

Chen Z, Trotman LC, Shaer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher,
HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandol PP. 2005. Crucial
role of p53-dependent cellular senescence in suppression of Pten-
decient tumorigenesis. Nature; 436:725730.

Cha MS, Lee MJ, Je GH, Kwak JY. 2001. Endogenous production of nitric oxide
by vascular endothelial growth factor down-regulates proliferation of
choriocarcinoma cells. Biochem Biophys Res Comm; 282(4):1061-1066.

Chambliss KL, Wu Q, Oltmann S, Konaniah ES, Umetani M, Korach KS, Thomas

GD, Mineo C, Yuhanna IS, Kim SH, Madak-Erdogan Z, Maggi A, Dineen

83
 SP, Roland CL, Hui DY, Brekken RA, Katzenellenbogen JA,
Katzenellenbogen BS, Shaul PW. 2010. Non-nuclear estrogen receptor-
signaling promotes cardiovascular protection but not uterine or breast
cancer growth in mice. J Clin Invest; 120:23192330.

Clark GM, Osborne CK, Levitt D, Wu F, Kim NW. 1997. Telomerase activity and
survival of patients with node-positive breast cancer. J Natl Cancer Inst;
89:18741881.

Cheung An, Zhang DK, Liu Y, et al. 1999. Telomerase activity in gestational
trophoblastic disease. J Clin Pathol; 52:588-592.

Chinni SR, Alhasan SA, Multani AS, Pathak S, Sarkar FH. 2003. Pleotropic
effects of genistein on MCF-7 breast cancer cells. Int J Mol Med;
12(1):29-34.

Cifuentes-Rojas C, Shippen DE. 2012. Telomerase regulation. Mutat Res

Fundam Mol Mech Mutagen; 730:2027.

Clarke M. 2006. Meta-analyses of adjuvant therapies for women with early breast
cancer: the Early Breast Cancer Trialists Collaborative Group overview.
Ann Oncol; 17 Suppl 10:5962.

Colitz CMH, Barden CA, Lu P, Chandler HL. 2006. Expression and

characterization of the catalytic subunit of telomerase in normal and
cataractous canine lens epithelial cells. Mol Vis; 12:10671076.

Corthorn J, Germain AA, Chac_on C, Rey S, Soto GX, Figueroa CD, et al. 2006.
Expression of kallikrein, bradykinin b2 receptor, and endothelial nitric
oxide synthase in placenta in normal gestation, preeclampsia, and
placenta accreta. Endocrine; 29:491-499.

Corey DR. 2002. Telomerase inhibition, oligonucleotides, and clinical trials.

Oncogene; 21:631637.

Costa M, Sourris K, Lim SM, Yu QC, Hirst CE, Parkington HC, Jokubaitis VJ,
Dear AE, Liu HB, Micallef SJ. Koutsis K, Elefanty AG, Stanley EG.2013.
Derivation of endothelial cells from human embryonic stem cells in fully
defined medium enables identification of lysophosphatidic acid and
platelet activating factor as regulators of eNOS localization. Stem Cell
Research; 10:103117.

de Lange T. 2005. Shelterin: the protein complex that shapes and safeguards
human telomeres. Genes & Dev; 19:21002110.

Denger S, Reid G, Kos M, Flouriot G, Parsch D, Brand H, Korach KS, Sonntag-

Buck V, Gannon F. 2001. ER- gene expression in human primary
osteoblasts: evidence for the expression of two receptor proteins. Mol
Endocrinol.; 15:20642077.

Diel P, Geis RB, Caldarelli A, Schmidt S, Leschowsky UL, Voss A, Vollmer G.

2004. The differential ability of the phytoestrogen genistein and of
estradiol to induce uterine weight and proliferation in the rat is

84
 associated with a substance specific modulation of uterine gene
expression. Mol Cell Endocrinol; 221:2132.

Dominguez R, Micevych P. 2010. Estradiol rapidly regulates membrane estrogen

receptor alpha levels in hypothalamic neurons. J Neurosci; 30:12589
12596.

Eros RB. 2004. Replicative senescence of CD8 T cells: potential eects on

cancer immune surveillance and immunotherapy. Cancer Immunoll &
Immunother 53:925933.

Forstermann U, Sessa WC. 2012. Nitric oxide synthases: regulation and function.
Eur Heart J; 33:829-837.

Flouriot G, Griffin C, Kenealy M, Sonntag-Buck V, Gannon F. 1998. Differentially

expressed messenger RNA isoforms of the human estrogen receptor-
gene are generated by alternative splicing and promoter usage. Mol
Endocrinol.; 12:19391954.

Frescas D, de Lange T. 2014 TRF2-tethered TIN2 can mediate telomere

protection by TPP1/POT1. Mol Cell Biol; 34(7):1349-1362.

Folini M, Colella G, Villa R, Lualdi S, Daidone MG, Zaaroni N, 2000. Inhibition of

telomerase activity by a hammerhead ribozyme targeting the RNA
component of telomerase in human melanoma cells. J Invest
Dermatology; 114:259267.

Folini M, Zaaroni N. 2005. Targeting telomerase by antisense-based

approaches: perspectives for new anti-cancer therapies. Current
Pharmaceutical Design; 11:11051117

Fukumura D, Kashiwagi S, Jain RK. 2006. The role of nitric oxide in tumour
progression. Nat Rev Cancer; 6:521-534.

Fulton D, Babbitt R, Zoellner S, Fontana J, Acevedo L, McCabe TJ, Iwakiri Y,

Sessa WC. 2004. Targeting of endothelial nitric-oxide synthase to the
cytoplasmic face of the Golgi complex or plasma membrane regulates
Akt- versus calcium-dependent mechanisms for nitric oxide release. J
Biol Chem 279 (29):3034930357.

Fulton D, Fontana, J, Sowa G, Gratton JP, Lin M, Li KX, Michell B, Kemp BE,
Rodman D, Sessa WC. 2002. Localization of endothelial nitric-oxide
synthase phosphorylated on serine 1179 and nitric oxide in Golgi and
plasmamembrane defines the existence of two pools of active enzyme. J
Biol Chem; 277(6):42774284.

Ghobrial IM, Wizig TE, Adjei AA. 2005. Targeting apoptosis pathways in cancer
therapy. CA Cancer J Clin; 55:178-194.

Gielis JF. Lin JY, Wingler K, Van Schil PEY, Schmidt HH, Moens AL. 2011.
Pathogenic role of eNOS uncoupling in cardiopulminary disorders. Free
Rad Biol Med; 50:765-776.

85
Gisselsson D, Jonson T, Petersen A, Strombeck B, Dal Cin P, Hoglund M,
Mitelman F, Mertens F, Mandahl N, 2001. Telomere dysfunction triggers
extensive DNA fragmentation and evolution of complex chromosome
abnormalities in human malignant tumors. Proc Natl Acad Sci USA:
23:1268312688.

Gobeil F, Jr, Zhu T, Brault S, Geha A, Vazquez-Tello A, Fortier A, Barbaz D,

Checchin D, Hou X, Nader M, Bkaily G, Gratton JP, Heveker N, Ribeiro-
da-Silva A, Peri K, Bard H, Chorvatova A, D'Orlans-Juste P, Goetzl EJ,
Chemtob S. 2006. Nitric oxide signaling via nuclearized endothelial
nitric-oxide synthase modulates expression of the immediate early
genes iNOS and mPGES-1. J Biol Chem; 281:1605816067.

Goetz RM, Thatte HS, Prabhakar P, Cho MR, Michel T, Golan DE. 1999.
Estradiol induces the calcium-dependent translocation of endothelial
nitric oxide synthase. Proc Natl Acad Sci USA; 96:27882793.

Gorosito SV, Lorenzo AG, Cambiasso MJ. 2008. Estrogen receptor alpha is
expressed on the cell-surface of embryonic hypothalamic neurons.
Neuroscience; 154:11731177.

Granger MP, Wright WE, Shay JW. 2002. Telomerase in cancer and aging. Crit
Rev Oncol/Hematol; 41:2940.

Grasselli A, Nanni S, Colussi C, Aiello A, Benvenuti V, et al. 2008. Estrogen

receptor-alpha and endothelial nitric oxide synthase nuclear complex
regulates transcription of human telomerase. Circ Res; 103:3442.

Grasselli A, Nanni S, Colussi C, Aiello A, Benvenuti V, Ragone G, Moretti F,

Sacchi A, Bacchetti S, Gaetano C, Capogrossi MC, Pontecorvi A,
Farsetti A. 2008. Estrogen receptor- and endothelial nitric oxide
synthase nuclear complex regulates transcription of human telomerase.
Circ Res; 103:3442.

Griffith JD, Comeau L, Rosenfield S, et al. 1999. Mammalian telomeres end in a

large duplex loop. Cell; 97:50314.

Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, De Lange

T. 1999. Mammalian telomeres end in a large duplex loop. Cell; 97:503
514.

Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon, P. 1986.

Human oestrogen receptor cDNA: sequence, expression and homology
to v-erb-A. Nature; 320:134139.

Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. 1986. Sequence

and expression of human estrogen receptor complementary DNA.
Science; 231:11501154.

Greider CW. 1998. Telomerase activity, cell proliferation, and cancer. Proc Natl
Acad Sci USA; 95:9092.

86
Hahn WC. 1999. Inhibition of telomerase limits the growth of human cancer cells.
Nature Med; 5:11641170.

Hannan NJ, Paiva P, Dimitriadis E, Salamonsen LA. 2010. Models for study of
human embryo implantation: choice of cell lines? Biol Reprod; 82:235-
245.

Harley CB, Futcher AB, Greider CW. 1990. Telomeres shorten during ageing of
human broblasts. Nature; 345:458460.

Harrington L, McPhail T, Mar V. 1997. A mammalian telomerase-associated

protein. Science; 275:973977.

Hauguel T, Bunz F. 2003. Haploid insufficiency of hTERT leads to telomerase

dysfunctions and radio sensitivity in human cancer cells. Cancer Biol
Ther; 2(6):679-684.

Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, Baron R, Collinge M, Sessa

WC, Bender JR. 2003. Src kinase mediates phosphatidylinositol 3-
kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation
by estrogen. J Biol Chem; 278:21182123.

He Q, Zeng P, Tan JH, Ou TM, Gu LG, Huang ZS, Li D. 2014. G-quadruplex-

mediated regulation of telomere binding protein POT1 gene expression.
Biochim et Biophyss Acta; 1840:22222233.

Hecker I, Mulsch A, Bassenge E, Frstermann U, Busse R. 1994. Subcellular

localization and characterization of nitric oxide synthase(s) in endothelial
cells: physiological implications. Biochem J; 299:247-252.

Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M,

Strom A, Treuter E, Warner M, Gustafsson JA. 2007. Estrogen
receptors: how do they signal and what are their targets. Physiol Rev;
87: 905-931.

Hemmens B, Mayer B. 1998. Enzymology of nitric oxide synthases. Meth Mol

Biol; 100:132.

Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA,
Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, Robinson BG, Learoyd
DL, Stalley PD, Bonar SF, Yu D, Pollock RE, Reddel RR. 2005. A robust
assay for alternative lengthening of telomeres in tumors shows the
signicance of alternative lengthening of telomeres in sarcomas and
astrocytomas. Clin Cancer Res; 11:217225.

Herbert BS, Wright AC, Passons CM. 2001. Effects of chemopreventive and
antitelomerase agents on the spontaneous immortalization of breast
epithelial cells. J Natl Cancer Inst; 93:3945.

Hirata S, Shoda T, Kato J, Hoshi K. 2003. Isoform/variant mRNAs for sex steroid
hormone receptors in humans. Trends Endocrinol Metab; 14:124129.

87
Hiyama E, Gollahon L, Kataoka T. 1996. Telomerase activity in human breast
tumours. J Natl Cancer Inst; 88:116122.

Hiyama E, Saeki T, Hiyama K. 2000. Telomerase activity as a marker of breast

carcinoma in fine-needle aspirated samples. Cancer Cytopathol;
90:235238.

Holt SE, Aisner D, Baur J. 1999. Functional requirement of p23 and hsp90 in
telomerase complexes. Gene Dev; 13:817826.

Holt SE, Shay JW. 1999. Role of telomerase in cellular proliferation and cancer. J
Cell Physiol; 180:1018.

Honor EK, Williams JK, Anthony MS, Clarkson TB. 1997. Soy isoflavones
enhance coronary vascular reactivity in atherosclerotic female
macaques. Fertil Steril; 67:148154.

Hussain SP, He P, Subleski J, Hofseth LJ, Trivers GE, Mechanic L, Hofseth AB,
Bernard M, Schwank J, Nguyen G, Mathe E, Djurickovic D, Haines D,
Weiss J, Back T, et al. 2008. Nitric oxide is a key component in
inflammation accelerated tumorigenesis. Cancer Res; 68:71307136.

Ishii H, Kobayashi M, Munetomo A, Miyamoto T, Sakuma Y. 2013. Novel splicing

events and post-transcriptional regulation of human estrogen receptor-
E isoforms. J. Steroid Biochem. Mol Biol;133:120128.

Jiang SW, Lloyd RV, Jin L, Eberhardt NL. 1997. Estrogen receptor expression
and growth-promoting function in human choriocarcinoma cells. DNA
Cell Biol 16:969-977.

Ju H, Zou R, Venema VJ, Venema RC. 1997. Direct interaction of endothelial

nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol
Chem; 272:1852218525.

Karlseder J, Smogorzewska A., de Lange T. 2002. Senescence induced by

altered telomere state, not telomere loss. Science; 295:24462449.

Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G,

Martini PG, McInerney EM, Delage-Mourroux R, Weis K,
Katzenellenbogen JA. 2000. Estrogen receptors: selective ligands,
partners, and distinctive pharmacology. Rec Prog Horm Res; 55:163
193.

Keith WN, Bilsland A, Hardie M, Evans TR. 2004. Drug insight: Cancer cell
immortality-telomerase as a target for novel cancer gene therapies.
Nature Clin Pract Oncol; 1:8896.

Khan KH, Blanco-Codesido M, Molife LR. 2014. Cancer therapeutics: Targeting

the apoptotic pathway. Critical Rev Oncol Hematol; 90:200219.

Khaw AK, Yong JW, Kalthur G, Hande MP. 2012. Genistein induces growth
arrest and suppresses telomerase activity in brain tumor cells. Genes
Chromosomes Cancer; 51(10):961-974.

88
Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. 2009. The SWISS-MODEL
repository and associated resources. Nucleic Acids Res; 37:387-392.

Kleinschmidt-Demasters BK, Evans LC, Bobak JB. 2000. Quantitative telomerase

expression in glioblastomas shows regional variation and down-
regulation with therapy but no correlation with patient outcome. Hum
Pathol; 31:905913.

Kim NW, Piatysek MA, Prowse M. 1994. Specific association of human

telomerase activity with immortal cells and cancer. Science; 266:2011
2015.

Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM,
Wright WE, Weinrich SL, Shay JW. 1994. Specic association of human
telomerase activity with immortal cells and cancer. Science; 266:2011
2015.

King A, Thomas L, Bischof P. Cell culture models of trophoblast, II: trophoblast

cell lines: a workshop report. Placenta 2000;21(Suppl. A):S113e9.

Klatt P, Pfeiffer S, List BM, Lehner D, Glatter O, Bachinger HP, Werner ER,
Schmidt K, Mayer B. 1996. Characterization of heme-deficient neuronal
nitric oxide synthase reveals a role for heme in subunit dimerization and
binding of the amino acid substrate and tetrahydrobiopterin. J Biol
Chem; 271:73367342.

Klinz FJ, Schmidt A, Schinkthe T, Arnhold S, Desai B, Popken F, Brixius K,

Schwinger R, Mehlhorn U, Staib P, Addicks K, Bloch W. 2005. Phospho-
eNOS Ser-114 in human mesenchymal stem cells: constitutive
phosphorylation, nuclear localization and upregulation during mitosis.
Eur J Cell Biol; 84:809818.

Kos M, Reid G, Denger S, Gannon F. 2001. Minireview: genomic organization of

the human Er gene promoter region. Mol Endocrinol; 15:20572063.

Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q,
Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R,
Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. 2002. Reversal of
bone loss in mice by nongenotropic signaling of sex steroids. Science;
298:843846.

Kradin R, Matsubara O, Mark EJ. 2005. Endothelial nitric oxide synthase

expression in pulmonary capillary hemangiomatosis. Exp Mol Pathol
79:194197.

Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S,

Gustafsson JA. 1997. Comparison of the ligand binding specificity and
transcript tissue distribution of estrogen receptors alpha and beta.
Endocrinol 138:863870.

89
Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. 1996. Cloning
of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad
Sci USA; 93:59255930.

Laskowski RA & Swindells MB. 2011. LigPlot+: multiple ligand-protein interaction

diagrams for drug discovery. J Chem Inf Model; 24(51): 2778-86

Langford LA, Piatyszek MA, Xu R, Schold SC, Shay JW. 1997. Telomerase
activity: a prognostic indicator in ordinary meningiomas. Hum Pathol;
28:416420.

Lavelle F, Riou JF, Laoui A, Mailliet P. 2000. Telomerase: a therapeutic target for
the third millennium?. Critical Rev in Oncol Hematol; 34:111126.

Le X, Wei D, Huang S, Lancaster Jr, JR, Xie K, 2005. Nitric oxide synthase II
suppresses the growth and metastasis of human cancer regardless of its
upregulation of protumor factors. Proc Natl Acad Sci USA; 102:8758
8763.

Li L, Haynes MP, Bender JR. 2003. Plasma membrane localization and function
of the estrogen receptor- variant (ER46) in human endothelial cells.
Proc Natl Acad Sci USA; 100:48074812.

Liao B, Patel M, Hu Y, Charles S, Herrick DJ, Brewer G. 2004. Targeted

knockdown of the RNA-binding protein CRD-BP promotes cell
proliferation via an insulin-like growth factor II-dependent pathway in
human K562 leukemia cells. J Biol Chem; 279:4871624.

Liu D, Homan LL, Dillon JS. 2004. Genistein acutely stimulates nitric oxide
synthesis in vascular endothelial cells by a cyclic adenosine 5-
monophosphate-dependent mechanism. Endocrinol; 145:55325539.

Liu X, Li X, Yin L, Ding J, Jin H, Feng Y. 2011. Genistein inhibits placental

choriocarcinoma cell line JAR invasion through ER/MTA3/Snail/E-
cadherin pathway. Oncol Lett; 2(5):891-897.

Liu J, Zou WG, Lang MF, Luo J, Sun LY, Wang XN, Qian QJ, Liu XY. 2002.
Cancer-specic killing by the CD suicide gene using the human
telomerase reverse transcriptase promoter. International J Oncol;
21:661666.

Long, S, Argyle DJ, Nixon C, Nicholson I, Botteron C, Olby N, Platt S, Smith K,

Ruttema GR, Grinwis GCM, Nasir L. 2006. An immunohistochemical
study of telomerase reverse transcriptase (TERT) and MIB-1 expression
in canine brain tumours. Neurobiology & Applied Neuropathol; 32:662
673.

Long S, Argyle DJ, Campbell S, Gault E, Nasir L. 2005. The canine telomerase
catalytic subunit (dogTERT): characterisation of the gene promoter and
identication of proximal core sequences necessary for specic
transcriptional activity in canine telomerase positive cell lines. Gene;
358:111120.

90
Longo M, Brama M, Marino M, Bernardini S, Korach KS, Wetsel WC, Scandurra
R, Faraggiana T, Spera G, Baron R, Teti A, Migliaccio S. 2004.
Interaction of estrogen receptor- with protein kinase C alpha and c-Src
in osteoblasts during differentiation. Bone; 34:100111.

Lurain JR, Brewer JI. 1982. Invasive mole. Semin Oncol; 9:174-180.

Lurain JR. 2010. Gestational trophoblastic disease I: epidemiology, pathology,

clinical presentation and diagnosis of gestational trophoblastic disease,
and management of hydatidiform mole. Am J Obstet Gynecol; 531-539.

Macindoe G, Mavridis L, Venkatraman V, Devignes MD, Ritchie DW. HexServer:

an FFT-based protein docking server powered by graphics processors.
Nucleic Acids Res 2010; 38:445-9.

Mrquez DC, Pietras RJ. 2001. Membrane-associated binding sites for estrogen
contribute to growth regulation of human breast cancer cells. Oncogene;
20:54205430.

Matsutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB, Brooks, M.W.,
Kaneko S, Murakami S, DeCaprio JA, Weinberg RA, Stewart SA, Hahn
WC. 2003. Telomerase maintains telomere structure in normal human
cells. Cell; 114:241253.

Mattila JT, Thomas AC. 2014. Nitric oxide synthase: non-canonical expression
patterns. Front Immunol; 5:478.

McKenna NJ, and OMalley BW. 2002. Combinatorial control of gene expression
by nuclear receptors and coregulators. Cell; 108:465474

Mtivier R, Penot G, Hbner MR, Reid G, Brand H, Kos M, Gannon F. 2003.

Estrogen receptor- directs ordered, cyclical, and combinatorial
recruitment of cofactors on a natural target promoter. Cell; 115:751763.

Michel JB, Feron O, Sacks D, Michel T. 1997. Reciprocal regulation of

endothelial nitric-oxide synthase by Ca2-calmodulin and caveolin. J
Biol Chem; 272:15583-15586.

Minshall RD, Sessa WC, Stan RV, Anderson RG, Malik AB. 2003. Caveolin
regulation of endothelial function. Am. J. Physiol. Lung Cell Mol Physiol;
285(6):L1179L1183.

Miracco C, Pacenti L, Santopietro R, Laurini L, Biagioli M, Luzi P. 2000.

Evaluation of telomerase activity in cutaneous melanocytic proliferations.
Hum Pathol; 31:10181021.

Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H,

Kuzushima K, Takiguchi M, Kaneko S, 2006. Cytotoxic T cell responses
to human telomerase reverse transcriptase in patients with
hepatocellular carcinoma. Hepatology; 43:12841294.

Montanaro D, Maggiolini M, Recchia AG, Sirianni R, Aquila S, Barzon L, Fallo F,

Ando S, Pezzi V. 2005. Antiestrogens upregulate estrogen receptor beta

91
 expression and inhibit adrenocortical H295R cell proliferation. J Mol
Endocrinol; 35:245256.

Morales CP, Holt SE, Ouellette M. 1999. Absence of cancer-associated changes

in human fibroblasts immortalized with telomerase. Nature Genet;
21:1158.

Mosselman S, Polman J, Dijkema R. 1996. ER beta: identification and

characterization of a novel human estrogen receptor. FEBS Lett; 392:
4953.

Muller CY, Cole LA. 2009. The quagmire of hCG and hCG testing in gynecologic
oncology. Gyneologic Oncol; 112:663-672.

Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J,
Harley CB, Cech TR. 1997. Telomerase catalytic subunit homologs from
ssion yeast and human. Science; 277:955959.

Nakayama J, Saito M, Nakarnura R. 1997. TLP 1: A gene encoding a protein

component of mammalian telomerase is a novel member of WD repeats
family. Cell; 88:875884.

Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, et al. 2009. Endothelial

NOS, estrogen receptor beta, and HIFs cooperate in the activation of a
prognostic transcriptional pattern in aggressive human prostate cancer.
J Clin Invest; 119:10931108.

Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, Colussi C,

Lirangi V, Illi B, D'Eletto M, Cianciulli AM, Gallucci M, De Carli P,
Sentinelli S, Mottolese M, Carlini P, Strigari L, Finn S, Mueller E,
Arcangeli G, Gaetano C, Capogrossi MC, Donnorso RP, Bacchetti S,
Sacchi A, Pontecorvi A, Loda M, Farsetti A. 2009. Endothelial NOS,
estrogen receptor , and HIFs cooperate in the activation of a prognostic
transcriptional pattern in aggressive human prostate cancer. J Clin
Invest; 119:10931108.

Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E,

Pettersson K, Warner M, Gustafsson JA. 2001. Mechanisms of estrogen
action. Physiol Rev 81:15351565.

Nishida CR, Ortiz de Montellano PR. 1998. Electron transfer and catalytic activity
of nitric oxide synthases: chimeric constructs of the neuronal, inducible,
and endothelial isoforms. J Biol Chem; 273:55665571.

Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K. 2004. Hypoxia-inducible

factor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol;
24(13):6076-6083.

Nozawa H, Watanabe T, Ohnishi T, et al. 2003. Detection of cancer cells in

mesenteric vein and peripheral vessels by measuring telomerase activity
in patients with colon rectal cancer. Surgery; 34(5):791-798.

92
Nugent CI, Lundblad V. 1998. The telomerase reverse transcriptase. Genes Dev;
12:107385.

OBoyle N, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR.

2011. Open Babel: An open chemical toolbox. Journal of
Cheminformatics; 3:33 doi:10.1186/1758-2946-3-33

OReilly M, Teichmann SA, Rhodes D. 1999. Telomerases. Curr Opin Struct Biol;
9:5665.

Ouchi H, Ishiguro H, Ikeda N, Hori M, Kubota Y, Uemura H. 2005. Genistein

induces cell growth inhibition in prostate cancer through the suppression
of telomerase activity. Int J Urol; 12(1):73-80.

Oufkir T, Arseneault M, Sanderson JT, Vaillancourt C. The 5-HT2A serotonin

receptor enhances cell viability, affects cell cycle progression and
activates MEK-ERK1/2 and JAK2-STAT3 signlling pathways in human
choriocarcinome cell lines. Placenta; 31:439-447.

Pallini R, Sorrentino A, Pierconti F, Maggiano N, Faggi R, Montano N, Maira G,

Larocca LM, Levi A, Falchetti ML. 2006. Telomerase inhibition by stable
RNA interference impairs tumor growth and angiogenesis in
glioblastoma xenografts. Int J Cancer; 118:21582167.

Park M, Bruice TC. 2010. Development of potential anticancer agents that target
the telomers sequence. Bioorg Med Chem; 20:3982-3986.

Patel J, Landers K, Li H, RH Mortimer, Richard K. 2011. Oxygen concentration

regulates expression and uptake of transthyretin, a thyroxine binding
protein, in JEG-3 choriocarcinoma cells. Placenta; 32:128-133.

Prabhakar P, Thatte HS, Goetz RM, Cho MR, DGolan DE, Michel T. 1998.
Receptor-regulated translocation of endothelial nitric-oxide synthase. J
Biol Chem; 273:27383-27388.

Qi DL, Ohhira T, Fujisaki C, Inoue T, Ohta T, Osaki M, Ohshiro E, Seko T, Aoki

S, Oshimura M, Kugoh H. 2008. Identification of PITX1 as a TERT
suppressor gene crossroads of cell fate. Cytogenet Genome Res;
122:263272.

Raman CS, Li H, Martasek P, Kral Vm Masters BS, Poulos TL. 1998. Crystal
structure of constitutive endothelial nitric oxide synthase: a paradigm for
pterin function involving a novel metal center. Cell; 95:939950.

Ramirez R, Morales CP, Shea-Herbert B. 2001. Putative telomere-independent

mechanisms of replicative aging eflect inadequate growth conditions.
Gene Dev; 15:398403.

Rameshbabu K, Sharma R, Singh KP, George A, Chauhan MS, Singla SK, et al.
2012. Presence of nitric oxide synthase immunoreactivity and mRNA in
buffalo (Bubalus bubalis) oocytes and embryos. Reprod Domest Anim;
47:22-25.

93
Rthel TR, Leikert JF, Vollmar AM, Dirsch VM. 2005. The soy isoflavone
genistein induces a late but sustained activation of the endothelial nitric
oxide-synthase system in vitro. Br J Pharmacol; 144:394399.

Raynaud CM, Sabatier L, Philipot O, Olaussen KA, Soria JC. 2008. Telomere
length, telomeric proteins and genomic instability during the multistep
carcinogenic process. Crit Rev Oncol Hematol; 66:99117.

Razani B, Schlegel A, Liu J, Lisanti MP. 2001. Caveolin-1, a putative tumour

suppressor gene. Biochem Soc Trans; 29:494499.

Refaat B, Simpson H, Britton E, Biswas J, Wells M, Aplin JD, et al. 2012. Why
does the fallopian tube fail in ectopic pregnancy? The role of activins,
inducible nitric oxide synthase, and MUC1 in ectopic implantation. Fertil
Steril; 97:1115-1123.

Reif A, Frohlich LG, Kotsonis P, Frey A, Bommel HM, Wink DA, Pfleiderer W,
Schmidt HH. 1999. Tetrahydrobiopterin inhibits monomerization and is
consumed during catalysis in neuronal NO synthase. J Biol Chem
274:2492124929.

Renwick MG, Argyle DJ, Long S, Nixon C, Gault EA, Nasir L. 2006. Telomerase
Activity and cTERT expression in canine lymphoma: correlation with
Ki67 immunoreactivity. Vet Comp Oncol; 4:141150.

Rettenmaier MA, Khan HJ, Epstein HD, Nguyen D, Abaid LN, GoldsteinBH.
2013. Gestational choriocarcinoma in the Fallopian tube. J Obstet
Gynaecol; 33(8):912914.

Ries L, Eisner M, Kosary C, Hankey BF, Miller BA, Clegg L, Edwards BK. 2001.
SEER Cancer Statistics Review, 19731998, Table II-3. Bethesda, MD:
National Cancer Institute: 137.

Rizzo V, McIntosh DP, Oh P, Schnitzer JE. 1998. In situ flow activates

endothelial nitric oxide synthase in luminal caveolae of endothelium with
rapid caveolin dissociation and calmodulin association. J Biol Chem;
273:34724-34729.

Rodier F, Kim SH, Nijjar T, Yaswen P, Campisi J. 2005. Cancer and aging: the
importance of telomeres in genome maintenance. Int J Biochem Cell
Biol; 37:977990.

Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR. 2000. Human vascular
endothelial cells contain membrane binding sites for estradiol, which
mediate rapid intracellular signaling. Proc Natl Acad Sci USA; 97:5930
5935.

Sato Y, Fujiwara H, Higuchi T, Yoshioka S, Tatsumi K, Maeda M, et al. 2002.

Involvement of dipeptidyl peptidase IV in extravillous trophoblast
invasion and differentiation. J Clin Endocrinol Metab; 87(9):4287-4296.

Sebire N, Lindsay L. 2010. Current issue in the histopathology of gestasional

trohphoblastic tumors. 29:30-44.

94
Sengupta J, Dhawan L, Lalitkumar PG, Ghosh D. 2005. Nitric oxide in blastocyst
implantation in the rhesus monkey. Reproduction; 130:321-32.

Sessa WC, Garcia-Cardena G, Liu J, Keh A, Pollock JS, Bradley J, Thiru S,

Braverman IM, Desai KM 1995. The golgi association of endothelial
nitric oxide synthase is necessary for the efficient synthesis of nitric
oxide. J Biol Chem; 270:17641-17644.

Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. 2000. Cofactor dynamics and

sufficiency in estrogen receptor-regulated transcription. Cell; 103:843
852.

Sharma S, Raymond E, Soda R. 1997. Preclinical and clinical strategies for

development of telomerase and telomere inhibitors. Ann Oncol; 8:1063
1074.

Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, Ying Y, Anderson
RG, Michel T. 1996. Acylation targets endothelial nitric-oxide synthase to
plasmalemmal caveolae. J Biol Chem; 271:6518-6522.

Shay JW, Gazdar AF. 1997. Telomerase in the early detection of cancer. J Clin
Pathol; 50:106109.

Shay JW, Bacchetti S. 1997. A survey of telomerase activity in human cancer.

Eur J Cancer; 33:787791.

Shay JW. 1998. Telomerase in cancer: diagnostic, prognostic, and therapeutic

implications. Cancer J Sci Am; Suppl 1:S2634.

Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Wang Z,

Xie Y. 2009. Expression of ER- 36, a novel variant of estrogen receptor
, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol;
27:34233429.

Simon NM, Smoller JW, McNamara KL, Maser RS, Zalta AK, Pollack MH,
Nierenberg AA, Fava M, Wong KK. 2006. Shortening and mood
disorders: preliminary support for a chronic stress model of accelerated
aging. Biol Psychiatry; 60:432435.

Si H, Yu J, Jiang H, Lum H, Liu D. 2012. Phytoestrogen genistein up-regulates

endothelial nitric oxide synthase expression via activation of cAMP
response element-binding protein in human aortic endothelial cells.
Endocrinol; 153(7):3190-3198.

Smith CL and OMalley BW. 2004. Coregulator function: a key to understanding

tissue specifity of selective receptor modulators. Endocr Rev; 25:4571

Smith HO, Kohorn E, Cole LA. 2005. Choriocarcinoma and gestational

trophoblastic disease. Obstet Gynecol Clin North Am; 32(4):661684.

Squadrito F, Altavilla D, Crisafulli A, Saitta A, Cucinotta D, Morabito N, D'Anna R,

Corrado F, Ruggeri P, Frisina N, Squadrito G. 2003. Effect of genistein

95
 on endothelial function in postmenopausal women: a randomized,
double-blind, controlled study. Am J Med; 114:470476.

Straszewski-Chavez SL, Abrahams VM, Alvero AB, Aldo PB, Ma Y, Guller S,

Romero R, Mor G. 2009. The isolation and characterization of novel
telomerase immortalized first trimester trophobals cell line, Swan 71.
Placenta; 939-948.

Szkudelska K, Nogowski L. 2007. Genistein a dietary compound inducing

hormonal and metabolic changes. J Steroid Biochem Mol Biol; 105:37-
45.

Tatsumoto N, Hiyama E, Murakami Y. 2000. High telomerase activity is an

independent prognostic indicator of poor outcome in colorectal
carcinoma. Clin Cancer Res; 6:2696701.

Taylor CK, Levy RM, Elliott JC, Burnett BP. 2009. The effect of genistein
aglycone on cancer and cancer risk: a review of in vitro, preclinical, and
clinical studies. Nutr Rev; 67:398-415.

Thomas T, Gallo MA, Thomas TJ. 2004. Estrogen receptors as targets for drug
development for breast cancer, osteoporosis and cardiovascular
disease. Curr Cancer Drug Targets; 4:483499.

Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston RN, Thompson

TC. 2000. Caveolin-1 is regulated by c-myc and suppresses c-myc-
induced apoptosis. Oncogene; 19:32563265.

Titu LV, Loveday RL, Madden LA, Cawkwell L, Monson JR, Greenman J. 2004.
Cytotoxic T-cell immunity against telomerase reverse transcriptase in
colorectal cancer patients. Oncology Rep; 12:871876.

Tsui KH, Li HY, Cheng JT, Sung YJ, Yen MS, Hsieh SLE, Wang PH. 2015. The
role of nitric oxide in the outgrowth of trophoblast cells on human
umbilical vein endothelial cells.Taiwan J Obstet Gynecol; 54:227-231.

van Dijk M, Bonvin AMJJ. 2008. 3D-DART: a DNA structure modelling server.
Nucleic Acids Res; 37:235-239.

Venema RC, Ju H, Zou R, Ryan JW, Venema, VJ. Subunit interactions of

endothelial nitric-oxide synthase: comparisons to the neuronal and
inducible nitric-oxide synthase isoforms. J Biol Chem; 272:12761282;
1997.

Venema VJ, Marrero MB, Venema RC. 1996. Bradykinin-stimulated protein

tyrosine phosphorylation promotes endothelial nitric oxide synthase
translocation to the cytoskeleton. Biochem Biophys Res Commun;
226:703-710.

Wang T, Mei SC, Fu R, Wang HQ, Shao ZH. 2014. Expression of shelterin
component POT1 is associated with decreased telomere length and
immunity condition in humans with severe aplastic anemia. J Immunol
Res; Article ID 439530, 9 pages.

96
Wang Q, Patton WF, Hechtman HB, Shepro D. 1997. A novel anti-inflammatory
peptide inhibits endothelial cell cytoskeletal rearrangement, nitric oxide
synthase translocation, and paracellular permeability increases. J Cell
Physiol; 172: 171-182.

Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. 2006. A variant of
estrogen receptor-, hER- 36: Transduction of estrogen- and
antiestrogen-dependent membrane-initiated mitogenic signaling. Proc
Natl Acad Sci USA; 103:90639068.

Wargasetia TL, Shahib N, Martaadisoebrata D, Dhianawaty D, Hernowo B.

Characterization of apoptosis and autophagy through Bcl-2 and Beclin-1
immunoexpression in gestational trophoblastic disease. Iran J Reprod
Med; 13(7):413-320.

Watson JD. 1972. The origin of concatemeric T7 DNA. Nature; 239:197201.

Weinrich SL, Pruzan R, Ma L. 1997. Reconstitution of human telomerase with the

template RNA component hTR and the catalytic protein subunit hTRT.
Nat Genet; 17:498502.

Witorsch RJ. 2002. Endocrine disruptors: can biological effects and

environmental risks be predicted? Regul Toxicol Pharmacol; 36:118
130.

Wong SC, Yu H, Moochhala SM, So JB. 2003. Antisense telomerase induced cell
growth inhibition, cell cycle arrest and telomerase activity down-
regulation in gastric and colon cancer cells. Anticancer Res; 23: 465
469.

Wright WE, Tesmer M, Huffinan KE. 1997. Normal human chromosomes have
long G-rich telomeric overhang at one end. Gene Dev; 11:28012809.

Wright WE, Shay JW. 2001. Cellular senescence as a tumor-protection

mechanism: the essential role of counting. Curr Opin Genet Dev; 11:98
103.

Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I, Aradi J, Lanotte

M, Tong JH, Chen GQ, Segal-Bendirdjian E. 2006. Immunodetection of
human telomerase reverse-transcriptase (hTERT) re-appraised:
nucleolin and telomerase cross paths. J Cell Sci: 119:27972806.

Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. 2002. The role of nitric oxide in
cancer. Cell Res; 12:311320.

Yi X, Tesmer VM, Savre-Train I, Shay JW, Wright WE. 1999. Both transcriptional
and posttranscriptional mechanisms regulate human telomerase
template RNA levels. Mol Cell Biol; 19:39893997.

Yoshiko T, Makoto K, Fuyuki I. 2000. Aging mechanisms. Proc Natl Acad Sci;
23:12407-408.

97
You Y, Pu P, Huang Q, Xia Z, Wang C, Wang G, Yu C, Yu JJ, Reed E, Li QQ.
2006. Antisense telomerase RNA inhibits the growth of human glioma
cells in vitro and in vivo. IntJ Oncol; 28:12251232.

Zaffaroni N, Villa R, Pennati M, Folini M. 2003. Approaches for the inhibition of

human telomerase based on the use of peptide nucleic acids and
hammerhead ribozymes. Mini Rev Med Chem; 3:5160.

Zhang Q, Church JE, Jagnandan D, Catravas JD, Sessa WC, Fulton D. 2006.
Functional relevance of Golgi- and plasma membrane-localized
endothelial NO synthase in reconstituted endothelial cells. Arterioscler
Thromb Vasc Biol; 26:10151021.

Zhu J, Wang H, Bishop JM, Blackburn EH. 1999. Telomerase extends the
lifespan of virus-transformed human cells without net telomere
lengthening. Proc Natl Acad Sci; 96:37238.

Zivadinovic D, Watson CS. 2005. Membrane estrogen receptor- levels predict

estrogen-induced ERK1/2 activation in MCF-7 cells. Breast Cancer Res;
7:R130144.

Zulli A, Buxton BF, Black MJ, Ming Z, Cameron A, Hare DL. 2006. The
immunoquantification of caveolin-1 and eNOS in human and rabbit
diseased blood vessels. J Histochem Cytochem; 54:151159.

Zundel W, Swiersz LM, Giaccia A. 2000. Caveolin 1-mediated regulation of

receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity
by ceramide. Mol Cell Biol; 20:15071514.

98